Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
Alan J KivitzJoel M KremerClarence W LegertonLuminita PricopAtul SinghalPublished in: Rheumatology and therapy (2024)
In this challenging sub-population of US patients with PsA, secukinumab provided rapid improvements in disease activity and QoL. Patients with PsA and active psoriasis might benefit more from secukinumab 300 mg than 150 mg.
Keyphrases